BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cenvacibart readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Cenvacibart\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07175428-11309@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20270209
DTEND;VALUE=DATE:20270210
SUMMARY:Cenvacibart: Phase 2 readout est. (NCT07175428)
DESCRIPTION:Cenvacibart\, phase 2.\nStudy: Safety in Adult Participants Wit
 h Atrial Fibrillation Who Are Treated With Anticoagulation\nEstimated prim
 ary completion: 9 February 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/cenvacibart#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07175428
URL:https://assetmemo.bio/drug/cenvacibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07015905-11309@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20270220
DTEND;VALUE=DATE:20270221
SUMMARY:Cenvacibart: Phase 3 readout est. (NCT07015905)
DESCRIPTION:Cenvacibart\, phase 3\, Venous Thromboembolism.\nStudy: REGN750
 8 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee A
 rthroplasty in Adults\nEstimated primary completion: 20 February 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/cenvacibart#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07015905
URL:https://assetmemo.bio/drug/cenvacibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07876505-11309@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20270323
DTEND;VALUE=DATE:20270324
SUMMARY:Cenvacibart: Phase 1 readout est. (NCT07876505)
DESCRIPTION:Cenvacibart\, phase 1.\nStudy: Healthy Adult Participants Trial
  Comparing Different Cenvacibart Presentations\nEstimated primary completi
 on: 23 March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ce
 nvacibart#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07876505
URL:https://assetmemo.bio/drug/cenvacibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07759167-11309@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20270402
DTEND;VALUE=DATE:20270403
SUMMARY:Cenvacibart: Phase 1 readout est. (NCT07759167)
DESCRIPTION:Cenvacibart\, phase 1.\nStudy: Study of 3 Monoclonal Antibodies
  (REGN9933\, REGN7508\, and REGN9533) in Adult Participants With End-Stage
  Kidney Disease on Hemodialysis\nEstimated primary completion: 2 April 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/cenvacibart#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07759167
URL:https://assetmemo.bio/drug/cenvacibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07213778-11309@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20270517
DTEND;VALUE=DATE:20270518
SUMMARY:Cenvacibart: Phase 3 readout est. (NCT07213778)
DESCRIPTION:Cenvacibart\, phase 3\, Venous Thromboembolism.\nStudy: REGN750
 8 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After To
 tal Knee Arthroplasty in Adult Participants\nEstimated primary completion:
  17 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cenvaci
 bart#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07213778
URL:https://assetmemo.bio/drug/cenvacibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07430956-11309@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20290328
DTEND;VALUE=DATE:20290329
SUMMARY:Cenvacibart: Phase 3 readout est. (NCT07430956)
DESCRIPTION:Cenvacibart\, phase 3.\nStudy: Stroke and Systemic Embolism Pre
 vention in Adult Participants With Atrial Fibrillation for Whom Oral Antic
 oagulation is Unsuitable\nEstimated primary completion: 28 March 2029. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/cenvacibart#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07430956
URL:https://assetmemo.bio/drug/cenvacibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07697599-11309@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20290625
DTEND;VALUE=DATE:20290626
SUMMARY:Cenvacibart: Phase 3 readout est. (NCT07697599)
DESCRIPTION:Cenvacibart\, phase 3\, Venous Thromboembolism.\nStudy: Venous 
 Thromboembolism (VTE) Prophylaxis With REGN7508 and REGN9933 in Adult and 
 Adolescent Participants With a Peripherally Inserted Central Catheter (PIC
 C)\nEstimated primary completion: 25 June 2029. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/cenvacibart#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07697599
URL:https://assetmemo.bio/drug/cenvacibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07318610-11309@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20290818
DTEND;VALUE=DATE:20290819
SUMMARY:Cenvacibart: Phase 3 readout est. (NCT07318610)
DESCRIPTION:Cenvacibart\, phase 3.\nStudy: Reducing Adverse Vascular Outcom
 es With Factor XI Inhibition in Adult Participants With Peripheral Artery 
 Disease\nEstimated primary completion: 18 August 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/cenvacibart#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07318610
URL:https://assetmemo.bio/drug/cenvacibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07626411-11309@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20290911
DTEND;VALUE=DATE:20290912
SUMMARY:Cenvacibart: Phase 3 readout est. (NCT07626411)
DESCRIPTION:Cenvacibart\, phase 3.\nStudy: Stroke and Systemic Embolism Pre
 vention in Adult Participants With Atrial Fibrillation\nEstimated primary 
 completion: 11 September 2029. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/cenvacibart#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07626411
URL:https://assetmemo.bio/drug/cenvacibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07876492-11309@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20291215
DTEND;VALUE=DATE:20291216
SUMMARY:Cenvacibart: Phase 3 readout est. (NCT07876492)
DESCRIPTION:Cenvacibart\, phase 3.\nStudy: A Study to Evaluate Cenvacibart 
 (REGN7508) for Secondary Stroke Prevention in Adult Participants\nEstimate
 d primary completion: 15 December 2029. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/cenvacibart#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07876492
URL:https://assetmemo.bio/drug/cenvacibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07410117-11309@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20300123
DTEND;VALUE=DATE:20300124
SUMMARY:Cenvacibart: Phase 3 readout est. (NCT07410117)
DESCRIPTION:Cenvacibart\, phase 3.\nStudy: REGN7508 in Adult Participants f
 or Prevention of Cancer-Associated Thrombosis\nEstimated primary completio
 n: 23 January 2030. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/c
 envacibart#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07410117
URL:https://assetmemo.bio/drug/cenvacibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07493304-11309@assetmemo.bio
DTSTAMP:20261121T004038Z
DTSTART;VALUE=DATE:20310718
DTEND;VALUE=DATE:20310719
SUMMARY:Cenvacibart: Phase 3 readout est. (NCT07493304)
DESCRIPTION:Cenvacibart\, phase 3\, Venous Thromboembolism.\nStudy: Treatme
 nt and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Parti
 cipants With Solid and Hematologic Cancers\nEstimated primary completion: 
 18 July 2031. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cenvaci
 bart#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07493304
URL:https://assetmemo.bio/drug/cenvacibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
